Results 61 to 70 of about 3,132 (216)
Ophthalmology (Rochester, Minn.)PURPOSE To evaluate the 24-week efficacy and safety of the dual angiopoietin-2 (Ang-2)/vascular endothelial growth factor-A (VEGF-A) inhibitor, faricimab, compared with aflibercept in patients with macular edema due to retinal vein occlusion (RVO ...
R. Tadayoni +15 more
semanticscholar +1 more source
Proteolytic remodelling of the extracellular matrix by pericytes
The FEBS Journal, Volume 293, Issue 13, Page 3899-3953, July 2026.Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard +4 more
wiley +1 more source
One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular Edema
, 2023 Ryan B Rush1– 3 1Panhandle Eye Group, Amarillo, TX, USA; 2Southwest Retina Specialists, Amarillo, TX, USA; 3Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USACorrespondence: Ryan B Rush, Southwest Retina Specialists ...
Rush RB
core
Acta Ophthalmologica, Volume 104, Issue 3, Page 296-304, May 2026.Abstract Purpose To evaluate visual, anatomical and safety outcomes of aflibercept 8 mg in previously treated patients with neovascular age‐related macular degeneration (nAMD). Methods This retrospective study included nAMD patients switched to aflibercept 8 mg from prior anti‐VEGF therapies at Sahlgrenska University Hospital between February 2024 and ...
Imadeddin Abu Ishkheidem +5 more
wiley +1 more source
Severe Intraocular Inflammation Following Intravitreal Faricimab.
JAMA ophthalmologyImportance Monitoring for and reporting potential cases of intraocular inflammation (IOI) in clinical practice despite limited occurrences in clinical trials, including experiences with relatively new intravitreal agents, such as brolucizumab ...
Loka Thangamathesvaran +7 more
semanticscholar +1 more source
Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia
Clinical &Experimental Ophthalmology, Volume 54, Issue 4, Page 500-506, May/June 2026.ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies +8 more
wiley +1 more source
Ophthalmology and TherapyThis is a summary of the original article ‟Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis”. DMO, a serious eye condition that can lead to vision loss in people with diabetes, is a significant health ...
Christian Bührer +4 more
doaj +1 more source
Graefe's Archive for Clinical and Experimental OphthalmologyAnti-vascular endothelial growth factor (VEGF) therapies have transformed the treatment of retinal diseases. However, VEGF signaling is only one component of the complex, multifactorial pathophysiology of retinal diseases, and many patients have residual
Varun Chaudhary +12 more
semanticscholar +1 more source
Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 3, March 2026.ABSTRACT Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing ...
Jennifer N. Clements +2 more
wiley +1 more source